{
    "1": {
        "workup": {
            "history and physical": [],
            "imaging": ["MRI and/or CT"],
            "pathology": [
                "Percutaneous core needle biopsy", 
                "Image-guided needle if its a deep-seated tumor",
                "Core needle biopsy after adequate imaging", 
                "Open biopsy if percutaneous core needle biopsies fail to lead to and adequate diagnosis and if there's an experienced surgeon"
            ],
            "other": {
                "Ancillary techniques": {
                    "Molecular genetic testing": [
                        "Fluorescence in situ hybridization (FISH)",
                        "Polymerase chain reaction (PCR)"
                    ],
                    "Immunohistochemistry": ["Cytogenetics"]
                }
            }
        }, 
        "treatment": {
            "surgical": [
                "Surgical wide resection with appropriately negative margins",
                "Re-resection to obtain negative margins", 
                "For extremity sarcomas, the goal is to preserve the functional limb"
            ],
            "radiation": [
                "Radiotherapy prior to surgery to enable effective surgical resection",
                "Postoperative radiotherapy if resections with close soft tissue margins (<1 cm) or a microscopically positive margin on bone, major bone vessels, or a nerve.",  
                "EBRT (external beam radiotherapy) 50-50.4 Gy;  1.8-2 Gy per fraction",
                {
                    "Brachytherapy ± EBRT": [
                        "Positive margins: Low dose-rate (16–20 Gy) or high dose-rate equivalent brachytherapy (14–16 Gy) + 50 Gy EBRT", 
                        "Negative margins: Low dose-rate (45 Gy) or high dose-rate equivalent brachytherapy (36 Gy in 3.6 Gy BID over 10 fractions in 5 days)" 
                    ]
                },
                "If adjuvant boost radiation for a positive margin is felt to be appropriate, an additional 14–20 Gy can be considered with fractionated EBRT or brachytherapy.",
                "A dose reduction to 36 Gy for myxoid liposarcoma can be considered.",
                "Radiotherapy if unresectable primary disease"
            ],
            "chemotherapy": ["Chemoradiation if resectable with adverse functional outcomes or unresectable primary disease"],
            "systemic": [
                "If resectable with adverse functional outcomes or unresectable primary disease",
                {
                    "Adjuvant systemic therapy": [
                        "AIM (doxorubicin, ifosfamide, mesna)",
                        "Ifosfamide, epirubicin, mesna"
                    ]
                }
            ],
            "observation": ["For stage 1A tumors"]
        }, 
        "followup": [
            "Evaluation for rehabilitation",
            "History and physical every 3-6 months for 2-3 years, then annually",
            "Consider chest imaging",
            "Consider obtaining adjuvant baseline MRI",
            "Imaging of primary site based on estimated risk of locoregional recurrence",
            "Physical Medicine and Rehabilitation" 
        ]
    },
    "2": {
        "workup": {
            "history and physical": [],
            "imaging": ["MRI and/or CT"],
            "pathology": [
                "Percutaneous core needle biopsy", 
                "Image-guided needle if its a deep-seated tumor",
                "Core needle biopsy after adequate imaging", 
                "Open biopsy if percutaneous core needle biopsies fail to lead to and adequate diagnosis and if there's an experienced surgeon" 
            ],
            "other": {
                "Ancillary techniques": {
                    "Molecular genetic testing": [
                        "Fluorescence in situ hybridization (FISH)",
                        "Polymerase chain reaction (PCR)"                        
                    ],
                    "Immunohistochemistry": ["Cytogenetics"]
                }
            }
        }, 
        "treatment": {
            "surgical": [
                "Surgical wide resection with appropriately negative margins",
                "Re-resection to obtain negative margins", 
                "For extremity sarcomas, the goal is to preserve the functional limb" 
            ],
            "radiation": [
                "Neoadjuvant radiotherapy", 
                "Postoperative radiotherapy", 
                "EBRT (external beam radiotherapy) 50-50.4 Gy;  1.8-2 Gy per fraction",
                {
                    "Brachytherapy ± EBRT": [
                        "Positive margins: Low dose-rate (16–20 Gy) or high dose-rate equivalent brachytherapy (14–16 Gy) + 50 Gy EBRT", 
                        "Negative margins: Low dose-rate (45 Gy) or high dose-rate equivalent brachytherapy (36 Gy in 3.6 Gy BID over 10 fractions in 5 days)"
                    ]
                },
                "If adjuvant boost radiation for a positive margin is felt to be appropriate, an additional 14–20 Gy can be considered with fractionated EBRT or brachytherapy.",
                "A dose reduction to 36 Gy for myxoid liposarcoma can be considered.",
                "Radiotherapy if unresectable primary disease"
            ],
            "chemotherapy": ["Chemoradiation if resectable with adverse functional outcomes or unresectable primary disease"],
            "systemic": [
                "If resectable with adverse functional outcomes or unresectable primary disease",
                {
                    "Adjuvant systemic therapy": [
                        "AIM (doxorubicin, ifosfamide, mesna)",
                        "Ifosfamide, epirubicin, mesna" 
                    ]
                } 
            ],
            "observation": [true]
        }, 
        "followup": [
            "Evaluation for rehabilitation",
            "History and physical every 3-6 months for 2-3 years, then every 6 months for next 2 years, then annually",
            "Chest imaging",
            "Obtain end-of-treatment and periodic imaging of primary site based on estimated risk of locoregional recurrence"
        ]
    },
    "3": {
        "workup": {
            "history and physical": [],
            "imaging": ["MRI and/or CT"],
            "pathology": [
                "Percutaneous core needle biopsy", 
                "Image-guided needle if its a deep-seated tumor",
                "Core needle biopsy after adequate imaging", 
                "Open biopsy if percutaneous core needle biopsies fail to lead to and adequate diagnosis and if there's an experienced surgeon" 
            ],
            "other": {
                "Ancillary techniques": {
                    "Molecular genetic testing": [
                        "Fluorescence in situ hybridization (FISH)",
                        "Polymerase chain reaction (PCR)"                        
                    ],
                    "Immunohistochemistry": ["Cytogenetics"]
                }
            }
        }, 
        "treatment": {
            "surgical": [
                "Surgical wide resection with appropriately negative margins",
                "Re-resection to obtain negative margins", 
                "For extremity sarcomas, the goal is to preserve the functional limb" 
            ],
            "radiation": [
                "Postoperative radiotherapy", 
                "Neoadjuvant therapy", 
                "Radiotherapy + adjuvant systemic therapy",
                "EBRT (external beam radiotherapy) 50-50.4 Gy;  1.8-2 Gy per fraction",
                {
                    "Brachytherapy ± EBRT": [
                        "Positive margins: Low dose-rate (16–20 Gy) or high dose-rate equivalent brachytherapy (14–16 Gy) + 50 Gy EBRT",
                        "Negative margins: Low dose-rate (45 Gy) or high dose-rate equivalent brachytherapy (36 Gy in 3.6 Gy BID over 10 fractions in 5 days)" 
                    ]
                },
                "If adjuvant boost radiation for a positive margin is felt to be appropriate, an additional 14–20 Gy can be considered with fractionated EBRT or brachytherapy.",
                "A dose reduction to 36 Gy for myxoid liposarcoma can be considered.",
                "Radiotherapy if unresectable primary disease"
            ],
            "chemotherapy": ["Chemoradiation if resectable with adverse functional outcomes or unresectable primary disease"],
            "systemic": [
                "If resectable with adverse functional outcomes or unresectable primary disease", 
                "Neoadjuvant systemic therapy/",
                {
                    "Adjuvant systemic therapy": [
                        "AIM (doxorubicin, ifosfamide, mesna)",
                        "Ifosfamide, epirubicin, mesna" 
                    ]
                }               
            ]
        }, 
        "followup": [
            "Evaluation for rehabilitation",
            "History and physical every 3-6 months for 2-3 years, then every 6 months for next 2 years, then annually", 
            "Chest imaging",
            "Obtain end-of-treatment and periodic imaging of primary site based on estimated risk of locoregional recurrence"
        ]
    },
    "4": {
        "workup": {
            "history and physical": [],
            "imaging": ["MRI and/or CT"],
            "pathology": [
                "Percutaneous core needle biopsy", 
                "Image-guided needle if its a deep-seated tumor",
                "Core needle biopsy after adequate imaging", 
                "Open biopsy if percutaneous core needle biopsies fail to lead to and adequate diagnosis and if there's an experienced surgeon"
            ],
            "other": {
                "Ancillary techniques": {
                    "Molecular genetic testing": [
                        "Fluorescence in situ hybridization (FISH)",
                        "Polymerase chain reaction (PCR)"                        
                    ],
                    "Immunohistochemistry": ["Cytogenetics"]
                }
            }
        }, 
        "treatment": {
            "primary": {
                "surgical": [
                    "Surgical wide resection with appropriately negative margins",
                    "Re-resection to obtain negative margins", 
                    "For extremity sarcomas, the goal is to preserve the functional limb"
                ],
                "radiation": [
                    "Postoperative radiotherapy", 
                    "Neoadjuvant therapy", 
                    "Radiotherapy + adjuvant systemic therapy",
                    "EBRT (external beam radiotherapy) 50-50.4 Gy;  1.8-2 Gy per fraction",
                    {
                        "Brachytherapy ± EBRT": [
                            "Positive margins: Low dose-rate (16–20 Gy) or high dose-rate equivalent brachytherapy (14–16 Gy) + 50 Gy EBRT", 
                            "Negative margins: Low dose-rate (45 Gy) or high dose-rate equivalent brachytherapy (36 Gy in 3.6 Gy BID over 10 fractions in 5 days)" 
                        ]
                    },
                    "If adjuvant boost radiation for a positive margin is felt to be appropriate, an additional 14–20 Gy can be considered with fractionated EBRT or brachytherapy.",
                    "A dose reduction to 36 Gy for myxoid liposarcoma can be considered.",
                    "Radiotherapy if unresectable primary disease"
                ],
                "chemotherapy": ["Chemoradiation if resectable with adverse functional outcomes or unresectable primary disease"],
                "systemic": [
                    "If resectable with adverse functional outcomes or unresectable primary disease",
                    "Neoadjuvant systemic therap",
                    {
                        "Adjuvant systemic therapy": [
                            "AIM (doxorubicin, ifosfamide, mesna)",
                            "Ifosfamide, epirubicin, mesna" 
                        ]
                    }
                ]
            },
            "Treatment if metastasis of a single organ and limited bulk that are amenable to local therapy": {
                "systemic": {
                    "Preferred regimens": {
                        "Anthracycline-based regimens": [
                            "Doxorubicin",
                            "Epirubicin",
                            "Liposomal doxorubicin",
                            "AD (doxorubicin, dacarbazine)",
                            "AIM",
                            "Ifosfamide, epirubicin, mesna"
                        ]
                    },
                    "Other recommended regimens": {
                        "Gemcitabine- based regimens": [
                            "Gemcitabine and docetaxel",
                            "Gemcitabine and vinorelbine",
                            "Gemcitabine and dacarbazine",
                            "Gemcitabine and pazopanib" 
                        ]
                    }
                },
                "surgery": [
                    "Metastasectomy",
                    "Ablation procedures"
                ],
                "radiation": [
                    "Radiotherapy",
                    "SBRT" 
                ],
                "other": ["Embolization procedures (no-lung metastases)"],
                "observation": [true]
            }
        }, 
        "followup": [
            "Evaluation for rehabilitation", 
            "History and physical every 2–6 months for 2–3 years, then every 6 months for next 2 years, then annually, if patient remains free of disease recurrence", 
            "Imaging of chest and other known sites of metastatic disease",
            "Consider obtaining adjuvant baseline and periodic imaging of primary site based on estimated risk of locoregional recurrence"
        ]
    },
    "5": {
        "workup": {
            "history and physical": [],
            "imaging": ["MRI and/or CT"],
            "pathology": [
                "Percutaneous core needle biopsy", 
                "Image-guided needle if its a deep-seated tumor",
                "Core needle biopsy after adequate imaging", 
                "Open biopsy if percutaneous core needle biopsies fail to lead to and adequate diagnosis and if there's an experienced surgeon" 
            ],
            "other": {
                "Ancillary techniques": {
                    "Molecular genetic testing": [
                        "Fluorescence in situ hybridization (FISH)",
                        "Polymerase chain reaction (PCR)"
                    ],
                    "Immunohistochemistry": ["Cytogenetics"]
                } 
            }
        }, 
        "palliative treatment": {
            "systemic": {
                "Preferred regimens": {
                    "Anthracycline-based regimens": [
                        "Doxorubicin",
                        "Epirubicin",
                        "Liposomal doxorubicin",
                        "AD (doxorubicin, dacarbazine)",
                        "AIM",
                        "Ifosfamide, epirubicin, mesna"
                    ]
                },
                "Other recommended regimens": {
                    "Gemcitabine- based regimens": [
                        "Gemcitabine and docetaxel",
                        "Gemcitabine and vinorelbine",
                        "Gemcitabine and dacarbazine",
                        "Gemcitabine and pazopanib" 
                    ]
                }
            },
            "surgical": [
                "Ablation procedures"
            ],
            "radiation": [
                "RT/SBRT"
            ],
            "observation": [true],
            "others": [
                "Supportive care",
                "Embolization procedures (no-lung metastases)"
            ]
        }, 
        "followup": [
            "individualized to the patient's clinical situation", 
            "Should include imaging" 
        ]
    },
    "6": {
        "workup": {
            "history and physical": [],
            "imaging": [
                "CT (preferred) or MRI", 
                "Consider PET/CT"
            ],
            "pathology": ["Image-guided core needle biopsy"],
            "other": ["Genetic assessment for patients with personal/family history suggestive of other cancer predisposition syndromes"]
        }, 
        "treatment": [
            "Regional node dissection for nodal involvement", 
            "RT",
            "Systemic therapy"
        ], 
        "followup": ["Follow up according to the stage, individualized"]
    },
    "7": {
        "workup": {
            "history and physical": [],
            "imaging": [
                "CT (preferred) or MRI", 
                "Consider PET/CT"
            ],
            "pathology": ["Image-guided core needle biopsy"],
            "other": ["Genetic assessment for patients with personal/family history suggestive of other cancer predisposition syndromes"]
        }, 
        "treatment": {
            "surgical": [
                "Surgery to obtain oncologically appropriate margins"
            ],
            "radiation": [
                "Neoadjuvant therapy",
                "Radiotherapy for tumors at high risk for local recurrence"
            ],
            "systemic": [
                "Neoadjuvant systemic therapy if high risk for metastatic disease"
            ]
        }, 
        "followup": ["Physical examination with imaging every 3–6 months for 2–3 years, then every 6 months for next 2 years, then annually"]
    },
    "8": {
        "workup": {
            "history and physical": [],
            "imaging": [
                "CT (preferred) or MRI", 
                "Consider PET/CT"
            ],
            "pathology": ["Image-guided core needle biopsy"],
            "other": ["Genetic assessment for patients with personal/family history suggestive of other cancer predisposition syndromes"]
        }, 
        "treatment": {
            "surgical": [
                "Surgery for symptom control"
            ],
            "radiation": [
                "Palliative radiotherapy"
            ],
            "other": ["Palliative or best supportive care"],
            "systemic": [
                "Systemic therapy"
            ],
            "observation": ["If asymptomatic and indolent tumor biology"]
        }, 
        "followup": ["Physical examination with imaging every 3–6 months for 2–3 years, then every 6 months for next 2 years, then annually"]
    },
    "9": {
        "workup": {
            "history and physical": [],
            "imaging": [
                "CT (preferred) or MRI", 
                "Consider PET/CT"
            ],
            "pathology": ["Image-guided core needle biopsy"],
            "other": ["Genetic assessment for patients with personal/family history suggestive of other cancer predisposition syndromes"]
        }, 
        "treatment": {
            "surgical": [
                "Surgery to obtain oncologically appropriate margins"
            ],
            "radiation": [
                "Neoadjuvant therapy if not previously given for the primary tumor"
            ],
            "systemic": [
                "Neoadjuvant therapy"
            ]
        }, 
        "followup": ["Physical examination with imaging every 3–6 months for 2–3 years, then every 6 months for next 2 years, then annually"]
    },
    "10": {
        "workup": {
            "history and physical": [],
            "imaging": ["Appropriate imaging of primary site with CT or MRI as clinically indicated"],
            "pathology": ["Biopsy"],
            "other": ["Consider evaluation for Gardner syndrome/familial adenomatous polyposis"]
        }, 
        "treatment": {
            "observation": ["Observation with imaging with CT or MRI as indicated and symptom management"]
        }, 
        "followup": {
            "If stable/regression": ["Consider ongoing observation with imaging with CT or MRI as indicated"],
            "If progression": [
                "Imaging with CT or MRI every 3-6 months for 2-3 years, then every 6-12 months thereafter",
                "ultrasound may be considered for selected locations (ie, abdominal wall) for long term follow up (ultrasound should be done by an ultrasonographer experienced in musculoskeletal disease)", 
                "evaluation for rehabilitation" 
            ]
        }
    },
    "11": {
        "workup": {
            "history and physical": [],
            "imaging": ["Appropriate imaging of primary site with CT or MRI as clinically indicated"],
            "pathology": ["Biopsy"],
            "other": ["Consider evaluation for Gardner syndrome/familial adenomatous polyposis"]
        }, 
        "treatment": {
            "surgical": [
                "Surgery if resectable"
            ],
            "systemic": [
                "Systemic therapy"
            ]
        }, 
        "followup": [
            "Imaging with CT or MRI every 3–6 months for 2–3 years, then every 6–12 months thereafter", 
            "Evaluation for rehabilitation"
        ]
    },
    "12": {
        "workup": {
            "history and physical": [],
            "imaging": ["Appropriate imaging of primary site with CT or MRI as clinically indicated"],
            "pathology": ["Biopsy"],
            "other": ["Consider evaluation for Gardner syndrome/familial adenomatous polyposis"]
        }, 
        "treatment": {
            "surgical": [
                "Surgery if resectable",
                "Ablation procedures"
            ],
            "radiation": [
                "Definitive radiotherapy"
            ],
            "systemic": {
                "Preferred regimens": [
                    "Sorafenib", 
                    "Methotrexate and vinorelbine", 
                    "Methotrexate and vinblastine", 
                    "Imatinib", 
                    "Liposomal doxorubicin"  
                ]
            }
        }, 
        "followup": [
            "Imaging with CT or MRI every 3–6 months for 2–3 years, then every 6–12 months thereafter",
            "Ultrasound may be considered for abdominal wall, for long-term followup.", 
            "Evaluation for rehabilitation"
        ]
    }
}